Security: Series C Preferred
Location: Louisville, CO

CEO: Tim Rodell
CMO: David Apelian
CBO: Jeff Rona

Board of Directors: Tim Rodell, Richard Duke, Darren Carroll, Chris Christoffersen, Ehud Geller, Gus Lawlor, Dan Mitchell, Paul Mieyal

New Investors: Wexford Capital, Celgene, Mellon Family Investment Company, Richard King Mellon Foundation, Eminent Venture Capital, Boston Life Science Venture, and WRF Capital

Existing Investors: HealthCare Ventures, Morgenthaler Ventures, Sequel Venture Partners, Lilly Ventures, Medica Venture Partners, Adams Street Partners, Biogen Idec, Pac-Link Bioventures, China Investment and Development, Yasuda Enterprise Development, Partners Healthcare, and GC&H Investments

- GlobeImmune is an immunotherapy company focused on the Tarmogen® platform for treating cancer and infectious diseases with a lead product candidate that has completed Phase 1b clinical trials for the treatment of chronic hepatitis C infection.

- Aquilo managed a global distribution effort and built a diverse syndicate of investors comprised of a large US hedge fund, US and Asian venture funds, a large foundation and a major biotechnology company.